Cost-utility - Globe Thesis

Keyword [Cost-utility] Result: 61 - 79 \| Page: 4 of 4
61.	A Study On The Influencing Factors And Cost-effectiveness Of Chinese Medicine Participating In The Treatment Of Cardiovascular Diseases In Middle-aged And Elderly People In My Country Based On The CHARLS Database
62.	A Cross-Sectional Study On Genitial Chlamydia Trachomatis Infection Among Population-Based Fertile Women And The Cost-Effectiveness Analysis Of Screening
63.	Effect Of Hearing Intervention On The Elderly With Cognitive Frailty And The Health Economic Evaluation Of The Intervention
64.	Sexual Behavior Changes And Medical Costs With Markov Analysis Of Rectal Swab Self-collection For Testing Chlamydia Trachomatis And Neisseria Gonorrhoeae In HIV-positive Men Who Have Sex With Men
65.	Cost-Utility Threshold For Malignant Tumor Population In China
66.	Pharmacoeconomic Evaluation Of Hypertension Drugs Based On Markov Model
67.	Economic Evaluation Of Abatacept Vs Adalimumab For The Treatment Of Patients With Moderate To Severe Rheumatoid Arthritis
68.	Cost-utility Analysis Of Atezolizumab Plus Bevacizumab Versus Sorafenib As First-line Therapy In Unresectable Or Metastatic Hepatocellular Carcinoma
69.	The Construction And Validation Of Evaluation Index System For Post-Marketing Chinese Patent Medicine Value With MCDA Model
70.	Cost-utility Analysis Of Different Venous Access In Cancer Patients Based On Decision Tree Model
71.	Evaluation Of The Value Of Selexipag In The Treatment Of Pulmonary Arterial Hypertension
72.	A Comprehensive Evaluation Of Three Original ARB/CCB Combinations For The Treatment Of Essential Hypertension With Poor Monotherapy Control
73.	A Cost-utility Analysis Of IGlarLixi Versus IDegAsp In The Treatment Of Type Ⅱ Diabetes Patients In China
74.	Interferon Gamma Release Assay For Diagnosis And Screening Of Tuberculosis Infection In Patients With Rheumatic Diseases:Systematic Review And Health Economics Evaluation
75.	Health Economics Evaluation Of Stroke Intervention Strategies In A Hypertensive Population
76.	Economic Evaluation Of Ensartinib For Patients With Anaplastic Lymphoma Kinase-positive Non-small-cell Lung Cancer In China
77.	Pharmaco-economic Evaluation Of Sintilimab For First-line Treatment Of Advanced Non-small Cell Lung Cancer
78.	Pharmacoeconomic Evaluation Of Carfilzomib In The Treatment Of Newly Diagnosed Multiple Myeloma
79.	Development And Health Economic Evaluation Of Cervical Cancer Screening Strategy Among Rural Women In Hubei Province
<<First <Prev Next> Last>> Jump to